Please assess the completion status of the following clinical trial:

Trial Title: Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has type 2 diabetes mellitus treated with diet modification and exercise alone or in combination with a stable regimen of a combination of metformin, sulphonylureas, and thiazolidinediones for a minimum of 2 months at screening.~* Hemoglobin A1c (HbA1c) of 7.1% to 11.0%, inclusive, at screening.~* Body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening.~* (For sub-study) Currently participating in open ended assessment period of main study 2993 LAR105~Exclusion Criteria:~* Has been previously exposed to exenatide (Byetta®), exenatide LAR, or any glucagon-like peptide-1 (GLP-1) analog.~* Received any investigational drug or has participated in any type of clinical trial within 30 days prior to screening.~* Has been treated, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications:~  * Alpha glucosidase inhibitor or meglitinide within 30 days of screening;~ * Insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening;~ * Regular use (\> 14 days) of drugs that directly affect gastrointestinal motility;~ * Regular use (\> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption;~ * Regular use (\> 14 days) of medications with addictive potential such as opiates and opioids;~ * Prescription or over-the-counter weight loss medications within 6 months of screening.~* (For sub-study) Subjects will be terminated from study who do not participate in the dual chamber pen substudy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exenatide Once Weekly (Type: EXPERIMENTAL): Subcutaneous injection (SC), once a week of long acting release (LAR) exenatide.
- Exenatide Twice Daily (Type: ACTIVE_COMPARATOR): subcutaneous injection (SC), twice a day for the first 30 weeks, followed by exenatide LAR SC injection weekly for the remainder of the study.~Sub-study: Exenatide 2 mg subcutaneous injection, Administered Using the Exenatide Once Weekly Single-Dose Tray , once a week for 11 visits, switch to Exenatide 2 mg subcutaneous injection, Administered Using the Dual chamber pen device. Exenatide 2mg SC injection administered using the Dual chamber pen device.

Based on this trial design, predict the completion outcome and termination type (if applicable).